Literature DB >> 26028304

SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.

Kenneth D Westover1, Puneeth Iyengar1, Akanksha Neeraj Sharma2, Robert Timmerman3.   

Abstract

Metastectomy has been performed for many years in situations where the functional consequences allow it, for example in the liver, lung, adrenal glands, and ovaries. This history suggests that selected patients may benefit from aggressive treatment of metastases. Technological developments now allow for ablative treatment of other tumor sites and perhaps for larger volume and/or increasing multiplicity of disease using Stereotactic Ablative Radiation Therapy (SABR) with relatively lower risk of morbidity to patients. Here we further explore the concept of aggressive local treatment of metastatic disease in adult patients and review the rationale for use of SABR to treat metastases and highlight new data supporting this approach in metastatic Non-Small Cell Lung Cancer.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Ablation; Metastases; NSCLC; Oligometastases; SABR; SBRT

Mesh:

Year:  2015        PMID: 26028304     DOI: 10.1016/j.lungcan.2015.04.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

Review 1.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

2.  Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer.

Authors:  Quoc-Anh Ho; Nima K Harandi; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2016-11-21       Impact factor: 4.785

Review 3.  Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.

Authors:  Neil B Desai; Aaron M Laine; Robert D Timmerman
Journal:  Br J Radiol       Date:  2016-12-23       Impact factor: 3.039

4.  Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer.

Authors:  Shao-Lun Lu; Feng-Ming Hsu; Kuan-Yu Chen; Chao-Chi Ho; James Chih-Hsin Yang; Jason Chia-Hsien Cheng
Journal:  Case Rep Oncol       Date:  2016-08-17

Review 5.  Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy.

Authors:  M Michelle Xu; Y Pu; R R Weichselbaum; Y-X Fu
Journal:  Oncogene       Date:  2016-07-18       Impact factor: 9.867

6.  Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors.

Authors:  Yu Jin Cha; Mi-Sook Kim; Won-Il Jang; Young Seok Seo; Chul Koo Cho; Hyung Jun Yoo; Eun Kyung Paik
Journal:  Radiat Oncol J       Date:  2017-06-30

7.  Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.

Authors:  Corey C Foster; David J Sher; Chad G Rusthoven; Vivek Verma; Michael T Spiotto; Ralph R Weichselbaum; Matthew Koshy
Journal:  Radiat Oncol       Date:  2019-01-28       Impact factor: 3.481

8.  Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma.

Authors:  Nikhil T Sebastian; Yubo Tan; Eric D Miller; Terence M Williams; Anne M Noonan; John L Hays; Sherif Abdel-Misih; Dayssy Alexandra Diaz
Journal:  JAMA Netw Open       Date:  2019-09-04

9.  Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases.

Authors:  Shuangshuang Li; Ju Yang; Juan Liu; Shanbao Gao; Baorui Liu; Jing Yan
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.